Fludarabine Base: A Potent Antineoplastic & Immunosuppressive Agent
ProcurenetShort description
Fludarabine Base is a robust antineoplastic and immunosuppressive agent, widely used for treating cancers like Chronic Lymphocytic Leukemia, Non-Hodgkin’s Lymphoma, and Acute Myeloid Leukemia. It functions by impeding DNA synthesis in cancer cells, which leads to their inactivity and eventual death.
- Composition: This white crystalline powder bears a molecular weight of 285.2 g/mol. It is water-soluble and slightly soluble in alcohol.
- Mechanism: Fludarabine Base disrupts the DNA synthesis, leading to cancer cell death.
- Storage: It should be stored at a room temperature between 20u00b0C and 25u00b0C (68u00b0F and 77u00b0F).
Caution is advised for pregnant or breastfeeding women, and people with renal or hepatic impairment. Regular monitoring for infections and secondary malignancies is crucial while on this medication.
-
Procurenet Team Tshim Sha Tsui
Hong Kong
3 years
Description
Fludarabine Base: A Potent Antineoplastic & Immunosuppressive Agent
Fludarabine Base is a purine analog that exhibits potent antineoplastic and immunosuppressive properties. It inhibits DNA synthesis by interfering with the action of essential enzymes such as ribonucleotide reductase and DNA polymerase, leading to cell cycle arrest and apoptosis in cancer cells.
Key Features:
- Potent antineoplastic and immunosuppressive properties resulting from interference with ribonucleotide reductase and DNA polymerase
- Effective in inducing cell cycle arrest and apoptosis in cancer cells.
- Can be administered orally or through injection. Typically used in its fludarabine phosphate form for clinical applications.
- Widely applied in the treatment of chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), and acute myeloid leukemia (AML).
Indications:
Fludarabine Base, primarily in its phosphate form, is used widely for treating various types of cancer. These include:
- Chronic Lymphocytic Leukemia (CLL): Fludarabine Base is a first-line treatment for CLL, either as a single agent or in combination with other chemotherapy drugs or monoclonal antibodies.
- Non-Hodgkin's Lymphoma (NHL): It forms part of combination chemotherapy regimens for both indolent and aggressive kinds of NHL.
- Acute Myeloid Leukemia (AML): Used in combination with other chemotherapy agents, such as cytarabine and idarubic.
